Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
berberine + bezafibrate
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of berberine and bezafibrate used for the treatment of mixed dyslipidemia. This combination has been shown to significantly reduce triglycerides, total cholesterol, LDL cholesterol, and VLDL levels in patients with mixed dyslipidemia. In clinical trials, the combination therapy remitted the diagnosis of mixed dyslipidemia in 90% of patients.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PPARA (Peroxisome proliferator-activated receptor alpha)LDLR (Low-density lipoprotein receptor)PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on berberine + bezafibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on berberine + bezafibrate.